🔴 GT Biopharma is trading 6% down today amid biotech weakness and a broader market sell-off

GT Biopharma is trading at $4.55, down 5.99%, amid biotech-sector weakness and a broader market sell-off.

• The wider market sell-off comes amid AI and data-center regulatory concerns.
• Searches surfaced no fresh company-specific announcement explaining the decline. The previously announced SITC presentation is scheduled for November 6, not a new November 5 catalyst.